Munir Ahmad., Zh.M.Umarov, F.Kh. Abboskhonova.

Tashkent medical academy

Dermatovenereology and Cosmetology Department

Objective: To compare the efficacy of low-dose immunosuppressive combination therapy with UVB-311nm versus UVB-311nm alone for the treatment of patients with vitiligo.

Materials and methods: 41 patients with vitiligo were divided into 2 groups: group 1 (27 people) received combination therapy with an immunosuppressor 25 mg once a day in combination with UVB 311-nm phototherapy, group 2 (14 people) received UVB-311 monotherapy nm. Patients were followed up for 1 month. Evaluation of the effectiveness of therapy was carried out on the basis of the VASI index (vitiligo prevalence and severity index).

Results: perifollicular repigmentation started on average after 3 sessions of UVB-311 nm in group 1 and 6 sessions in group 2. During the control of blood parameters in group 1, no deviations from the reference values ​​were observed. There were no significant side effects from therapy in both groups. After 2 months of therapy, pronounced repigmentation of lesions in group 1 was observed in 10 (47.8%) patients, in group 2 in 4 (20.7%) patients. When analyzing the results of therapy, the VASI index decreased by an average of 70% in patients of group 1, in group 2 – by 30%.

Conclusions: An immunosuppressant may potentiate repigmentation in combination with UVB-311nm in patients with non-segmental vitiligo. The use of this combination therapy is a promising treatment for vitiligo, but further studies are required with the inclusion of a larger sample of patients.